Table 1.
Current clinical trials for pluripotent stem cell replacement therapy for Parkinson’s Disease.
| Sponsor | BlueRock Therapeutics (US) | Region Skane (UK, Sweden) | Aspen Neuroscience (US) | UCSD / Sumitomo / Kyoto University (US, Japan) |
|---|---|---|---|---|
| US Government Trial ID (ClinicalTrials.gov) |
NCT04802733 Phase 1 |
NCT05635409 Phase 1 |
NCT06344026 Phase 1 |
NCT06482268 Phase 1 |
| Drug Product | MSK-DA01 (Embryonic stem cell-derived dopaminergic neurons) |
STEM-PD (Embryonic Stem Cell Derived Dopaminergic Progenitors) |
ANPD001 (iPS Cell-derived Dopaminergic Progenitors) |
CT1-DAP001 (iPS Cell-derived Dopaminergic Progenitors) |
| Cell Source | Allogeneic | Allogeneic | Autologous | Allogeneic |
| Rehabilitation Program | No | No | No | No |
| Start Date | May 3rd, 2021 | November 30th, 2022 | January 23rd, 2024 | June 1st, 2024 |
| Primary Outcome Measures | Safety (SAE §, abnormal tissue overgrowth) |
Safety (SAE, abnormal tissue overgrowth) |
Safety (SAE) |
Safety (SAE, graft overgrowth) |
§
“Serious Adverse Events”